238 related articles for article (PubMed ID: 37255469)
1. Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.
Le Terrier C; Nordmann P; Freret C; Seigneur M; Poirel L
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0033923. PubMed ID: 37255469
[TBL] [Abstract][Full Text] [Related]
2. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
Blanco-Martín T; Alonso-García I; González-Pinto L; Outeda-García M; Guijarro-Sánchez P; López-Hernández I; Pérez-Vázquez M; Aracil B; López-Cerero L; Fraile-Ribot P; Oliver A; Vázquez-Ucha JC; Beceiro A; Bou G; Arca-Suárez J;
Int J Antimicrob Agents; 2024 May; 63(5):107150. PubMed ID: 38513748
[TBL] [Abstract][Full Text] [Related]
3. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
Le Terrier C; Freire S; Nordmann P; Poirel L
Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
[TBL] [Abstract][Full Text] [Related]
4. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
[TBL] [Abstract][Full Text] [Related]
5. Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of
Le Terrier C; Nordmann P; Buchs C; Poirel L
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0154823. PubMed ID: 38415988
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.
Le Terrier C; Nordmann P; Poirel L
J Antimicrob Chemother; 2022 Dec; 78(1):101-107. PubMed ID: 36308322
[TBL] [Abstract][Full Text] [Related]
7. Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.
Poirel L; Ortiz de la Rosa JM; Sadek M; Nordmann P
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0003922. PubMed ID: 35315685
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates.
Le Terrier C; Nordmann P; Sadek M; Poirel L
J Antimicrob Chemother; 2023 May; 78(5):1191-1194. PubMed ID: 36921067
[TBL] [Abstract][Full Text] [Related]
9. New β-Lactam-β-Lactamase Inhibitor Combinations.
Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
[TBL] [Abstract][Full Text] [Related]
10.
Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan.
Kuo SC; Wang YC; Tan MC; Huang WC; Shiau YR; Wang HY; Lai JF; Huang IW; Lauderdale TL
J Antimicrob Chemother; 2021 Jul; 76(8):2071-2078. PubMed ID: 33956969
[TBL] [Abstract][Full Text] [Related]
12. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing
Vázquez-Ucha JC; Lasarte-Monterrubio C; Guijarro-Sánchez P; Oviaño M; Álvarez-Fraga L; Alonso-García I; Arca-Suárez J; Bou G; Beceiro A;
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0167621. PubMed ID: 34807754
[TBL] [Abstract][Full Text] [Related]
14.
Santerre Henriksen A; Jeannot K; Oliver A; Perry JD; Pletz MW; Stefani S; Morrissey I; Longshaw C;
Microbiol Spectr; 2024 Apr; 12(4):e0383623. PubMed ID: 38483164
[TBL] [Abstract][Full Text] [Related]
15. Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
Lee SY; Gill CM; Nicolau DP;
J Antimicrob Chemother; 2023 Dec; 78(12):2795-2800. PubMed ID: 37840005
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.
Wang X; Zhao C; Wang Q; Wang Z; Liang X; Zhang F; Zhang Y; Meng H; Chen H; Li S; Zhou C; Li H; Wang H
J Antimicrob Chemother; 2020 Jul; 75(7):1850-1858. PubMed ID: 32154866
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
[TBL] [Abstract][Full Text] [Related]
18. Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain.
Vázquez-Ucha JC; Alonso-Garcia I; Guijarro-Sánchez P; Lasarte-Monterrubio C; Álvarez-Fraga L; Cendón-Esteve A; Outeda M; Maceiras R; Peña-Escolano A; Martínez-Guitián M; Arca-Suárez J; Bou G; Beceiro A;
Int J Antimicrob Agents; 2023 Apr; 61(4):106738. PubMed ID: 36736925
[TBL] [Abstract][Full Text] [Related]
19. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae.
Tselepis L; Langley GW; Aboklaish AF; Widlake E; Jackson DE; Walsh TR; Schofield CJ; Brem J; Tyrrell JM
Int J Antimicrob Agents; 2020 Jul; 56(1):105925. PubMed ID: 32084512
[TBL] [Abstract][Full Text] [Related]
20. Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant
Zalacain M; Achard P; Llanos A; Morrissey I; Hawser S; Holden K; Toomey E; Davies D; Leiris S; Sable C; Ledoux A; Bousquet J; Castandet J; Lozano C; Everett M; Lemonnier M
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0112023. PubMed ID: 38289044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
